BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
For over three decades, LOGIQ has been at the forefront of ultrasound imaging, providing clinicians with reliable, high-quality solutions. The latest...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
Pfizer Inc. has announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union, marki...
ProNephro AKI (NGAL) stands out as the first AKI biomarker test to secure FDA clearance for pediatric use, covering children from...
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
CMR Surgical (CMR), a global leader in surgical robotics, has announced the appointment of Sushobhan Dasgupta as President and Chief Commercial Officer for...
Vetter, a globally recognized contract development and manufacturing organization (CDMO), proudly announces the successful market introduction of eight cus...
Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion...
Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceler...
© 2025 Biopharma Boardroom. All Rights Reserved.
